title: Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine.
abstract: The breaking of immune tolerance against autologous angiogenic endothelial cells should be a useful approach for cancer therapy. Here we show that immunotherapy of tumors using fixed xenogeneic whole endothelial cells as a vaccine was effective in affording protection from tumor growth, inducing regression of established tumors and prolonging survival of tumor-bearing mice. Furthermore, autoreactive immunity targeting to microvessels in solid tumors was induced and was probably responsible for the anti-tumor activity. These observations may provide a new vaccine strategy for cancer therapy through the induction of an autoimmune response against the tumor endothelium in a cross-reaction.
authors.affiliation: Center for Biotherapy of Cancer and Cancer Center, First University Hospital, West China University of Medical Sciences (HuaXi Medical School, Sichuan University), Guo Xue Xiang, The People's Republic of Chin. yuaquawei@mail.sc.cninfo.net
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Wei
authors.forename: Q R
authors.initials: QR
authors.lastname: Wang
authors.forename: X
authors.initials: X
authors.lastname: Zhao
authors.forename: L
authors.initials: L
authors.lastname: Yang
authors.forename: L
authors.initials: L
authors.lastname: Tian
authors.forename: Y
authors.initials: Y
authors.lastname: Lu
authors.forename: B
authors.initials: B
authors.lastname: Kang
authors.forename: C J
authors.initials: CJ
authors.lastname: Lu
authors.forename: M J
authors.initials: MJ
authors.lastname: Huang
authors.forename: Y Y
authors.initials: YY
authors.lastname: Lou
authors.forename: F
authors.initials: F
authors.lastname: Xiao
authors.forename: Q M
authors.initials: QM
authors.lastname: He
authors.forename: J M
authors.initials: JM
authors.lastname: Shu
authors.forename: X J
authors.initials: XJ
authors.lastname: Xie
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Mao
authors.forename: S
authors.initials: S
authors.lastname: Lei
authors.forename: F
authors.initials: F
authors.lastname: Luo
authors.forename: L Q
authors.initials: LQ
authors.lastname: Zhou
authors.forename: C E
authors.initials: CE
authors.lastname: Liu
authors.forename: H
authors.initials: H
authors.lastname: Zhou
authors.forename: Y
authors.initials: Y
authors.lastname: Jiang
authors.forename: F
authors.initials: F
authors.lastname: Peng
authors.forename: L P
authors.initials: LP
authors.lastname: Yuan
authors.forename: Q
authors.initials: Q
authors.lastname: Li
authors.forename: Y
authors.initials: Y
authors.lastname: Wu
authors.forename: J Y
authors.initials: JY
authors.lastname: Liu
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D015703:Antigens, CD / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000494:pharmacology*; D002417:Cattle; D002478:Cells, Cultured; D003429:Cross Reactions; D004727:Endothelium / Q000166:cytology* / Q000276:immunology*; D004730:Endothelium, Vascular / Q000166:cytology / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D039564:Integrin alphaV; D051379:Mice; D008969:Molecular Sequence Data; D009374:Neoplasms, Experimental / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000276:immunology; D010455:Peptides / Q000276:immunology; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology; D017978:Receptors, Growth Factor / Q000276:immunology; D040262:Receptors, Vascular Endothelial Growth Factor
chemical_list: D015703:Antigens, CD; D001323:Autoantibodies; D019496:Cancer Vaccines; D039564:Integrin alphaV; D010455:Peptides; D017978:Receptors, Growth Factor; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor